Skip to main content

Table 1 The characteristics of included RCTs

From: The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review

Study ID Sample size   Interventions Durations Outcomes
  Experimental group Control group   Experimental group Control group   
Azuma 2005 72 35   Pirfenidone 1800 mg/d Placebo 9 months Pirfenidone is not yet able to increase the lowest SpO2 in 6MWT, but it can increase the VC of IPF patients
CAPACITY 004 2011 174 174   Pirfenidone 2403 mg/d Placebo 72 weeks Pirfenidone slowed the decline of FVC and prolonged the PFS period, but did not significantly increase the lowest SpO 2 of 6MWD and 6MWT
CAPACITY 006 2011 171 173   Pirfenidone 2403 mg/d Placebo 72 weeks Pirfenidone did not increase the lowest SpO 2 in FVC, PFS phase and 6MWT, but pirfenidone could reduce the decline of 6MWD
Huang 2015 38 38   Pirfenidone 1800 mg/d Placebo 48 weeks The pirfenidone group can significantly prolong the PFS period, without significantly delaying the decline of FVC, and not increasing the lowest SpO2 of 6MWD and 6MWT
King 2014 (ASCEND) 278 277   Pirfenidone 1800 mg/d Placebo 52 weeks Pirfenidone can slow down the decline of FVC and 6MWD, and significantly prolong the PFS
Lei 2018 20 20   Pirfenidone 1200 mg/d Blank control 48 weeks Pirfenidone can delay the decline of FVC
Li 2015 43 44   Pirfenidone 1200 mg/d Placebo 48 weeks Pirfenidone can improve FVC and slow down the decline of 6MWD
Li 2016 24 24   Pirfenidone 1200 ~ 1800 mg/d Blank control 6 months Pirfenidone can improve FVC and increase 6MWD
Taniguchi 2010 110 109   Pirfenidone 1800 mg/d Placebo 52 weeks Pirfenidone can slow down the decline of VC in IPF patients and prolong the PFS
  1. PFS progression-free survival, VC vital capacity, FVC forced vital capacity